MOLN
Molecular Partners AG
NASDAQ · Healthcare · Biotechnology · CH
$4.11
−5.52%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-98.6%
Return on equity
-76.3%
Return on assets
-94.1%
Return on invested capital
0.00x
Asset turnover
-$63.8M
Cash from operations
$2.19
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026